DR-3001a
BR-OXY-202
Phase 2 small_molecule completed
Quick answer
DR-3001a for Urinary Incontinence is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Urinary Incontinence
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed